-
Featured
Mortality in COVID-19 Does Not Appear to Be Driven by Liver Failure
Massachusetts General Hospital researchers report that elevated liver function tests are common in COVID-19, but severe liver injury is rare, and no case of liver failure or dysfunction leading to death has been attributed directly to COVID-19.
-
Featured
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Featured
Early Transplantation for Alcohol-associated Hepatitis Improves Survival
According to a mathematical model, offering liver transplantation with no minimum period of sobriety before surgery (i.e., early liver transplantation) for severe alcohol-associated hepatitis provides a fourfold increase in life expectancy compared with requiring a six-month period of sobriety before listing. having characteristics similar to patients in ACCELERATE-AH trial.
-
Review: The Evolving Role of Quantitative Ultrasound for Fatty Liver Disease
Arinc Ozturk, MD, Anthony E. Samir, MD, MPH, and colleagues say advances in ultrasound hardware, signal processing, computational efficiency, and analytic algorithm development have led to exciting new quantitative tools that promise to increase the reliability of diagnosing hepatic steatosis.
-
Developing a Personalized Approach for Targeted Radiotherapy of Liver Cancers
Researchers at Massachusetts General Hospital are developing computation models capable of increasing the precision of targeted delivery of radiotherapy to liver tumors.
-
Tobacco Use and Type 2 Diabetes Have Additive Effect on Risk of Fibrosis in Patients With MASLD
Oluwafemi Balogun, MBBS, MPH, Kathleen E. Corey, MD, MPH, MMSc, and colleagues demonstrated that smoking and underlying type 2 diabetes mellitus (T2DM) have a synergistic effect on the severity of fibrosis, nearly doubling the risk (OR, 1.88; P=0.0037) compared with nonsmokers who do not have T2DM.
Liver Contributors
-
Emily D. Bethea, MD
Associate Clinical Director of Liver Transplantation, Massachusetts General Hospital
-
Jagpreet Chhatwal, PhD
Associate Director, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Recent Article
County-level COVID-19 Data Confirms Effectiveness of Workplace Closure -
Kathleen E. Corey, MD, MPH, MMSc
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit, Associate Professor of Medicine, Harvard Medical School
Recent Article
Tobacco Use and Type 2 Diabetes Have Additive Effect on Risk of Fibrosis in Patients With MASLD -
Raymond T. Chung, MD
Vice Chief, Division of Gastroenterology, Director, Hepatology and Liver Center, Massachusetts General Hospital
Recent Article
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV -
Russell P. Goodman, MD, DPhil
Hepatologist, Division of Gastroenterology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Imbalance of Electrons in the Liver May Be A Risk Factor for Many Common Diseases